Bruker Acquires DISQVER Clinical Metagenomics Platform

Bruker Corporation has acquired the DISQVER clinical metagenomics platform from Noscendo GmbH.

About the DISQVER Platform

DISQVER enables metagenomic next-generation sequencing (mNGS) analysis of microbes directly from blood samples, further expanding Bruker’s NGS-based infection detection capabilities.

Without any need for prior cultivation, DISQVER analyzes whole genome sequencing (WGS) data and applies advanced, proprietary bioinformatics to search for more than 11,000 different microbes and parasites. The mNGS analysis can be done directly from cell-free DNA samples from blood, in less than 24 hours after sample receipt. This advanced mNGS clinical research approach can be valuable for bloodstream infections, sepsis, endocarditis and other severe infectious diseases.

“The acquisition of the DISQVER proprietary software and workflow platform is the latest step in our evolution as an innovative microbiology and molecular diagnostics business,” said Dr. Wolfgang Pusch, President of Bruker Microbiology & Infection Diagnostics. “DISQVER adds additional NGS applications to our portfolio for metagenomics, and enhances our support for earlier decision-making in sepsis, bloodstream infections, and severe infections.”

Following the acquisition, DISQVER remains available for research use only, while Bruker is progressing its registration for diagnostic purposes.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.